Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Expected to Post Earnings of $0.12 Per Share

Wall Street brokerages expect Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) to report earnings per share of $0.12 for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Catalyst Pharmaceuticals’ earnings. The highest EPS estimate is $0.23 and the lowest is $0.08. Catalyst Pharmaceuticals posted earnings of ($0.14) per share in the same quarter last year, which would suggest a positive year over year growth rate of 185.7%. The business is expected to report its next earnings results on Monday, March 16th.

On average, analysts expect that Catalyst Pharmaceuticals will report full-year earnings of $0.37 per share for the current year, with EPS estimates ranging from $0.31 to $0.49. For the next financial year, analysts forecast that the company will report earnings of $0.52 per share, with EPS estimates ranging from $0.35 to $0.68. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. The business had revenue of $30.90 million during the quarter, compared to analyst estimates of $33.19 million. Catalyst Pharmaceuticals had a net margin of 12.99% and a return on equity of 15.53%.

Several brokerages recently weighed in on CPRX. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, October 31st. SunTrust Banks reaffirmed a “buy” rating and issued a $11.00 price objective (up from $9.00) on shares of Catalyst Pharmaceuticals in a research report on Thursday, August 8th. Piper Jaffray Companies cut their target price on Catalyst Pharmaceuticals from $8.00 to $7.00 in a research note on Wednesday, November 13th. Cantor Fitzgerald increased their target price on Catalyst Pharmaceuticals from $10.00 to $12.00 in a research note on Thursday, August 8th. Finally, ValuEngine lowered Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 30th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $8.95.

Shares of NASDAQ CPRX traded up $0.15 during midday trading on Friday, hitting $4.71. The stock had a trading volume of 471,980 shares, compared to its average volume of 2,354,569. The business’s 50 day moving average is $4.89 and its 200-day moving average is $4.79. Catalyst Pharmaceuticals has a 52 week low of $1.85 and a 52 week high of $7.67. The company has a quick ratio of 5.00, a current ratio of 5.04 and a debt-to-equity ratio of 0.01. The company has a market cap of $482.27 million, a P/E ratio of -14.27 and a beta of 2.38.

In related news, CEO Patrick J. Mcenany bought 10,000 shares of the firm’s stock in a transaction on Thursday, October 3rd. The stock was acquired at an average cost of $4.89 per share, for a total transaction of $48,900.00. Following the purchase, the chief executive officer now owns 4,772,693 shares in the company, valued at $23,338,468.77. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, insider Gary Ingenito sold 100,000 shares of the business’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $4.50, for a total transaction of $450,000.00. Following the sale, the insider now owns 100,000 shares of the company’s stock, valued at $450,000. The disclosure for this sale can be found here. 10.70% of the stock is currently owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in CPRX. Tower Research Capital LLC TRC bought a new stake in shares of Catalyst Pharmaceuticals in the third quarter worth $27,000. Meeder Asset Management Inc. increased its position in Catalyst Pharmaceuticals by 678.1% during the second quarter. Meeder Asset Management Inc. now owns 13,251 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 11,548 shares during the last quarter. Bank of Montreal Can lifted its holdings in Catalyst Pharmaceuticals by 159.1% in the second quarter. Bank of Montreal Can now owns 12,953 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 7,953 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new position in Catalyst Pharmaceuticals in the second quarter valued at about $55,000. Finally, Paradigm Capital Management Inc. NY bought a new position in Catalyst Pharmaceuticals in the second quarter valued at about $77,000. Hedge funds and other institutional investors own 59.80% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.

Read More: Preferred Stock

Get a free copy of the Zacks research report on Catalyst Pharmaceuticals (CPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.